{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:02:12Z","timestamp":1775678532172,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bbrc.2022.05.024","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T02:24:39Z","timestamp":1652408679000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Anisodamine potently inhibits SARS-CoV-2 infection in\u00a0vitro and targets its main protease"],"prefix":"10.1016","volume":"616","author":[{"given":"Wei","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.05.024_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bbrc.2022.05.024_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s43856-021-00015-1","article-title":"High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in long-term care facilities","volume":"1","author":"Pablo","year":"2021","journal-title":"Commun. Med."},{"key":"10.1016\/j.bbrc.2022.05.024_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.alit.2021.04.003","article-title":"Allergy to COVID-19 vaccines: a current update","volume":"70","author":"Cabanillas","year":"2021","journal-title":"Allergol. Int."},{"key":"10.1016\/j.bbrc.2022.05.024_bib5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2022.05.024_bib6","first-page":"1","article-title":"An update on current therapeutic drugs treating COVID-19","author":"Wu","year":"2020","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/j.bbrc.2022.05.024_bib7","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acsinfecdis.0c00343","article-title":"Old drugs for a new virus: repurposed approaches for combating COVID-19","volume":"6","author":"Saul","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bbrc.2022.05.024_bib8","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.pharmthera.2021.107843","article-title":"Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms","volume":"225","author":"Huang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2022.05.024_bib9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/bph.13486","article-title":"Possible role for anisodamine in organophosphate poisoning","volume":"173","author":"Eisenkraft","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2022.05.024_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jat.1154","article-title":"The pharmacological properties of anisodamine","volume":"27","author":"Poupko","year":"2007","journal-title":"J.\u00a0Appl. Toxicol."},{"key":"10.1016\/j.bbrc.2022.05.024_bib11","first-page":"327","article-title":"Anisodamine as an effective drug to treat snakebites","volume":"8","author":"Li","year":"1999","journal-title":"J.\u00a0Nat. Toxins"},{"key":"10.1016\/j.bbrc.2022.05.024_bib12","first-page":"452","article-title":"Patients of severe acute respiratory syndrome with hypoxemia treated by anisodamine","volume":"15","author":"Yang","year":"2003","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"10.1016\/j.bbrc.2022.05.024_bib13","doi-asserted-by":"crossref","first-page":"5818107","DOI":"10.1155\/2020\/5818107","article-title":"Network pharmacology integrated molecular docking reveals the mechanism of anisodamine hydrobromide injection against novel coronavirus Pneumonia","volume":"2020","author":"Su","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.bbrc.2022.05.024_bib14","doi-asserted-by":"crossref","first-page":"595342","DOI":"10.3389\/fimmu.2020.595342","article-title":"Activation of the cholinergic anti-inflammatory pathway as a novel therapeutic strategy for COVID-19","volume":"11","author":"Qin","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2022.05.024_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2022.05.024_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2022.05.024_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","volume":"11","author":"Gao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2022.05.024_bib18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2022.05.024_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2022.05.024_bib20","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1021\/jm101625x","article-title":"Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity","volume":"54","author":"Macias","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2022.05.024_bib21","first-page":"1","article-title":"Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2","author":"Khelfaoui","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2022.05.024_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0958-1669(02)00374-9","article-title":"No false start for novel pseudotyped vectors","volume":"13","author":"Sanders","year":"2002","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.bbrc.2022.05.024_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph13b03s51","article-title":"High-throughput screening of viral entry inhibitors using pseudotyped virus","author":"Basu","year":"2010","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.bbrc.2022.05.024_bib24","doi-asserted-by":"crossref","first-page":"104269","DOI":"10.1016\/j.bioorg.2020.104269","article-title":"Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19","volume":"104","author":"Faheem","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2022.05.024_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jinf.2020.06.017","article-title":"The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection","volume":"81","author":"Ha","year":"2020","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.bbrc.2022.05.024_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12985-020-01369-z","article-title":"SARS-CoV-2: characteristics and current advances in research","volume":"17","author":"Yang","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.bbrc.2022.05.024_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.bbrc.2022.05.024_bib28","doi-asserted-by":"crossref","first-page":"114227","DOI":"10.1016\/j.bcp.2020.114227","article-title":"AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication","volume":"182","author":"Rayner","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2022.05.024_bib29","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22007203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22007203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:17:37Z","timestamp":1757765857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22007203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":28,"alternative-id":["S0006291X22007203"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.05.024","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anisodamine potently inhibits SARS-CoV-2 infection in\u00a0vitro and targets its main protease","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}